Results 51 to 60 of about 165,283 (121)

Diagnostic findings and yield of investigations for children with developmental regression

American Journal of Medical Genetics Part A, Volume 194, Issue 8, August 2024.
Abstract Childhood conditions that feature developmental regression are poorly understood. Phenotype–genotype characterization and diagnostic yield data are needed to inform clinical decision‐making. The aim of this study was to report the conditions featuring developmental regression and assess diagnostic yields of investigations.
Kirsten Furley, Matthew F. Hunter, Michael Fahey, Katrina Williams   +3 more
wiley   +1 more source

Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases

Clinical and Translational Science, Volume 17, Issue 8, August 2024.
Abstract Real‐world evidence (RWE) has an increasing role in preapproval settings to support the approval of new medicines and indications. The main objectives of this study were to identify and characterize regulatory use cases that utilized RWE and other related observational approaches through targeted review of publications and regulatory review ...
Golnoosh Alipour‐Haris, Xinyue Liu, Virginia Acha, Almut G. Winterstein, Mehmet Burcu   +4 more
wiley   +1 more source

Noticiário

, 2001
Alfa, Revista
core   +9 more sources

Alfa-Cakes-Fabrik, Radebul-Dresden

ALFA-CAKES-FABRIK, RADEBUL-DRESDEN Alfa-Cakes-Fabrik, Radebul-Dresden ( -
Alfa-Cakes-Fabrik
core   +3 more sources

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? [PDF]

, 2011
INTRODUCTION: Previous cost-effectiveness analyses (CEA) reported that Drotrecogin alfa (DrotAA) is cost-effective based on a Phase III clinical trial (PROWESS).
Brian H Cuthbertson, Harrison, David A, Richard Grieve, Grieve, Richard, David A Harrison, M Zia Sadique, Kathryn M Rowan, Cuthbertson, Brian H, Rowan, Kathryn M, Sadique, M Zia   +9 more
core   +1 more source

ePosters Virtual

European Journal of Neurology, Volume 32, Issue S1, June 2025.
wiley   +1 more source

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

, 2004
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy ...
PEGINTERFERON ALFA A. HBEAG NEGATIVE CHRONIC HEPATITIS B. STUDY GROUP, MARCELLIN P, BONINO, FERRUCCIO, LAU GK   +3 more
core  

Peripapillary Retinal Nerve Fiber Layer (pRNFL) Thickness – A Novel Biomarker of Neurodegeneration in Late-Infantile CLN2 Disease

Eye and Brain
Nikolaos Gkalapis,1,2,* Simon Dulz,1,* Carsten Grohmann,1 Miriam Nickel,3 Christoph Schwering,3 Eva Wibbeler,3 Martin Stephan Spitzer,1 Angela Schulz,3 Yevgeniya Atiskova1 1Department of Ophthalmology, University Medical Center Hamburg-Eppendorf,
Gkalapis N, Dulz S, Grohmann C, Nickel M, Schwering C, Wibbeler E, Spitzer MS, Schulz A, Atiskova Y   +8 more
doaj  

Alfa Card

Card for Alfa, a hotel, restaurant, and garage.
Alfa Hotel
core  

Alfa-Cakes-Fabrik G.m.b.H, Radebeul-Dresden, Befreiungshalle.

ALFA-CAKES-FABRIK G.M.B.H, RADEBEUL-DRESDEN, BEFREIUNGSHALLE. Alfa-Cakes-Fabrik G.m.b.H, Radebeul-Dresden, Befreiungshalle. ( -
Alfa-Cakes-Fabrik G.m.b.H.
core   +1 more source